China is the fourth major market in which the treatment, sold under the brand name Kisunla, has received approval after the ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has ...

China has approved Eli Lillys Kisunla, marking another milestone in global efforts to address Alzheimers disease. The ...

Eli Lilly and Co. (LLY) said that the National Medical Products Administration (NMPA) in China has approved Kisunla (donanemab-azbt, ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option after Eisai and Biogen's Leqembi received approval in January ...

Since Novo's blockbuster Ozempic diabetes treatment was approved in the United States in 2017, regulators have greenlighted ...

The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in ...

The approval of Kisunla in China is based on a press release statement from Eli Lilly and Company and offers a new avenue for addressing the challenges of Alzheimer's disease in a population with ...